Innovation Center performance 2021
Sales were 9% lower compared to 2020, as DSM Biomedical continued to be impacted by the postponement of elective surgeries due to the COVID-19 pandemic and by negative foreign exchange effects. Adjusted EBITDA was up versus 2020, driven by higher technology licensing income.
x € million |
|
2021 |
|
2020 |
|---|---|---|---|---|
|
|
|
|
|
Net sales from continuing operations |
|
168 |
|
184 |
Organic sales growth (in %, continuing operations) |
|
(4) |
|
1 |
Adjusted EBITDA from continuing operations |
|
26 |
|
21 |
Adjusted operating profit from continuing operations |
|
4 |
|
(17) |
Capital expenditure |
|
2 |
|
35 |
Capital employed at 31 December |
|
407 |
|
436 |
R&D expenditure |
|
45 |
|
60 |
Workforce at 31 December (headcount) |
|
578 |
|
579 |
DSM Biomedical
DSM Biomedical is committed to solving some of our world’s key healthcare challenges through sustainable science and is a trusted partner to the global medical device and pharmaceutical industry, enhancing the quality and delivery of healthcare through innovative and sustainable biomaterials. As of 1 January 2022, DSM Biomedical will be part of the Health, Nutrition & Care Business Group.
Our top innovations and partnerships in 2021
In 2021, DSM Biomedical and Chemelot InSciTe research consortium started the first-in-human clinical trial for novel scoliosis treatment. The research consortium, consisting of physicians and researchers from Maastricht UMC+ (Netherlands) and Eindhoven University of Technology (Netherlands), works to reduce the severe complications scoliosis patients routinely suffer from corrective surgery.
We added ComfortCoat® Single Layer coating to our expanding portfolio of innovative, next-generation hydrophilic coatings. Our clinical partners in vascular interventions are achieving best-in-class particulate performance and significant operational efficiencies, now in a more sustainable way.
Our customer Svelte Medical achieved premarket approval for its SLENDER IDS sirolimus-eluting coronary stent-on-a-wire Integrated Delivery System, which contains DSM Biomedical’s polyester-amide (PEA)-based drug delivery material. Coronary stenting has been established as the standard of care for keeping the heart’s coronary artery open and is saving many lives.
Our innovations in both our polyurethanes and polyethylenes materials platforms have enabled our partners to successfully progress through safety trials and to progress into human clinical trials for next-generation structural heart devices (including transcatheter valve replacement).
DSM Bio-based Products & Services
DSM reached an agreement with International Flavors & Fragrances, Inc.’s (IFF) Health & Biosciences division in June 2021 for commercializing DSM’s advanced yeast technology for first-generation ethanol production. Under the terms of this agreement, DSM’s eBoost® product line became part of IFF’s XCELIS® Ethanol Solutions platform, completing our licensing strategy and subsequently the discontinuation of DSM Bio-based Products & Services.
DSM Advanced Solar
DSM successfully completed the sale of the coatings activities of DSM Advanced Solar to Covestro AG in April 2021 as part of the sale of DSM Resins & Functional Materials and related businesses. This was followed by the successful sale of the remaining DSM Advanced Solar activities to Worthen Industries, Inc. in June 2021.
